Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)
Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –
Zevra Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Zevra Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $82.38M. For fiscal 2025 it was -$62.94M. The highest annual figure on record is $7.73M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$62.94M | – |
| FY2024 | Dec 31, 2024 | -$87.00M | – |
| FY2023 | Dec 31, 2023 | -$49.60M | – |
| FY2022 | Dec 31, 2022 | -$42.57M | -650.7% |
| FY2021 | Dec 31, 2021 | $7.73M | – |
| FY2020 | Dec 31, 2020 | -$5.61M | – |
| FY2019 | Dec 31, 2019 | -$20.34M | – |
| FY2018 | Dec 31, 2018 | -$55.90M | – |
| FY2017 | Dec 31, 2017 | -$33.37M | – |
| FY2016 | Dec 31, 2016 | -$37.48M | – |
| FY2015 | Dec 31, 2015 | -$22.81M | – |
| FY2014 | Dec 31, 2014 | -$16.44M | – |
| FY2013 | Dec 31, 2013 | -$4.72M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $16.78M | – |
| Q1 FY2026 | Mar 31, 2026 | $52.15M | – |
| Q4 FY2025 | Dec 31, 2025 | $9.32M | – |
| Q3 FY2025 | Sep 30, 2025 | $4.14M | – |
| Q2 FY2025 | Jun 30, 2025 | -$71.04M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.36M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.42M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.80M | – |
| Q1 FY2024 | Mar 31, 2024 | -$20.49M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.16M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.25M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.83M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.63M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.77M | -524.6% |
| Q1 FY2022 | Mar 31, 2022 | -$1.86M | -126.7% |
| Q4 FY2021 | Dec 31, 2021 | -$2.84M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.22M | – |
| Q2 FY2021 | Jun 30, 2021 | $5.83M | +125.0% |
| Q1 FY2021 | Mar 31, 2021 | $6.96M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.21M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.21M | -137.5% |
| Q2 FY2020 | Jun 30, 2020 | $2.59M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.78M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.41M | – |
| Q3 FY2019 | Sep 30, 2019 | $3.23M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.79M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.37M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.27M | – |
| Q3 FY2018 | Sep 30, 2018 | -$17.96M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.91M | – |
| Q1 FY2018 | Mar 31, 2018 | -$14.77M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.15M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.61M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.22M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.38M | – |
| Q4 FY2016 | Dec 31, 2016 | -$10.84M | – |
| Q3 FY2016 | Sep 30, 2016 | -$10.40M | – |
See a number that looks wrong?